search
Back to results

Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson Disease

Primary Purpose

Parkinson Disease

Status
Unknown status
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
L-DOPS
Placebo
Sponsored by
St. Joseph's Hospital and Medical Center, Phoenix
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Parkinson Disease focused on measuring L-dihydoxyphenylserine, L-DOPS, Northera

Eligibility Criteria

30 Years - 83 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subject has voluntarily signed and dated an informed consent form (ICF) prior to any participation in the study.
  • Hoehn and Yahr Stage II, III, IV in an "on" state.
  • Fell more than twice in past year.
  • Montreal Cognitive Assessment (MOCA) score ≥ 24.
  • Stable dose of levodopa, dopamine agonist, amantadine, and/or monoamine oxidase B inhibitor, i.e. unchanged for 3 months.
  • Subject is ambulatory and able to walk ≥ 10 meters with/without the use of an assistive device.

Exclusion Criteria:

  • Patients with atypical Parkinson disorders that result in a high number of falls.These disorders include: Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), Primary Freezing of Gait (PFG), and Corticobasal Degeneration.
  • Patients with dementia MOCA ≤ 23.
  • Patients with symptomatic Orthostatic Hypotension being treated with midodrine, fludrocortisone or L-DOPS.
  • Patients with uncontrolled hypertension.
  • Patients with known allergies to L-DOPS or its excipients.
  • Patients with major orthopedic problems of their hips or knees, and patients who need hip or knee replacements.
  • Patient with schizophrenia, a schizo-affective disorder, or a bipolar disorder.
  • Patients with hallucinations, psychoses, or delusions.
  • Patients with a history of recent stroke or myocardial infarction.

Sites / Locations

  • Barrow Neurological Institute/St. Joseph's Hospital and Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

L-DOPS

Placebo

Arm Description

All participants will be on levodopa/carbidopa, and may be on additional dopaminergic drugs including dopamine agonists and/or monoamine type B oxidase inhibitors or amantadine. L-dihydoxyphenylserine will be added, administered as an oral capsule 3 times a day for 4 months. Dosing will begin at 100 mg of L-DOPS three times per day and titrated upward, by 100 mg three times a day, as tolerated. Tolerability will be evaluated based upon questionnaires, patient interviews, vital signs and investigator examination. In order to participate in the study, all subjects must be able to tolerate a minimum tolerated dose of 400 mg three times per day (1200mg/day). Subject maximum dose will be 600 mg three times per day (1800mg/day). Patients will be maintained on this dose for 4 months (until the cross-over). After a 7-day washout, participants will cross over to the Placebo arm.

All participants will be on levodopa/carbidopa, and may be on additional dopaminergic drugs including dopamine agonists and/or monoamine type B oxidase inhibitors or amantadine. Placebo will be added, administered as an oral capsule 3 times a day for 4 months. Dosing will begin at 100 mg of placebo three times per day and titrated upward, by 100 mg three times a day, as tolerated. Tolerability will be evaluated based upon questionnaires, patient interviews, vital signs and investigator examination. In order to participate in the study, all subjects must be able to tolerate a minimum tolerated dose of 400 mg three times per day (1200mg/day). Subject maximum dose will be 600 mg three times per day (1800mg/day). Patients will be maintained on this dose for 4 months (until the cross-over) After a 7-day washout, participants will cross over to the L-DOPS arm.

Outcomes

Primary Outcome Measures

Motor Score
Measured with United Parkinson's Disease Rating Scale (Part III 0-45) in the medication state of "on", "off", or both.
Balance Score
Measured using Barrow Neurologic Institute (BNI) Balance Scale 0-20, in the medication state of "on", "off", or both.
Postural Stability
Measured using a NeuroCom Equitest System, which tests sensory organization, motor control time, and postural sway measures, in the medication state of "on", "off", or both.
Dynamic Stability
Dynamic stability is measured by wearable devices (Inertial Measurement Units) that collect gait parameters during gait and postural transitions,in the medication state of "on", "off", or both.
Falls
Incidence of falls is self-report, in the medication state of "on", "off", or both.

Secondary Outcome Measures

Freezing of Gait (FOG)
Measured using United Parkinson's Disease Rating Scale (FOG subtests 2.13 and 3.11) 0-8, in the medication state of "on", "off", or both.
Apathy
Measured using Apathy in Parkinson's Disease Questionnaire 0-42, in the medication state of "on", "off", or both.
Orthostatic Hypotension
Measured using Orthostatic Hypotension Symptom Assessment 0-10,in the medication state of "on", "off", or both.

Full Information

First Posted
May 25, 2016
Last Updated
February 11, 2019
Sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Collaborators
Arizona State University
search

1. Study Identification

Unique Protocol Identification Number
NCT02812147
Brief Title
Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson Disease
Official Title
Effect of L-Dihydoxyphenylserine (L-DOPS, Northera) a Central and Peripheral Norepinephrine Agent on Locomotion, Postural Stability (Balance), and Fall Risk Reduction in Parkinson Disease (PD)
Study Type
Interventional

2. Study Status

Record Verification Date
February 2019
Overall Recruitment Status
Unknown status
Study Start Date
May 2016 (undefined)
Primary Completion Date
June 2019 (Anticipated)
Study Completion Date
June 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Collaborators
Arizona State University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This research study is being done to determine whether treatment with L- Dihydroxyphenylserine (L-DOPS) versus placebo (an inactive substance that looks like study drug) in addition to other Parkinson Disease (PD) drugs will improve balance, walking, and reduce risk of falls and/or severity of falls in PD subjects. The study is also being done to determine the effectiveness, safety, and tolerability of L-DOPS, and whether it will decrease Freezing of Gait (FOG), improve apathy (generalized disinterest) or show a relationship between apathy and slowed movement and fall risk.
Detailed Description
Among the top three priorities presented to the National Institute of Neurological Disorders and Stroke (NINDS) Council 22 as final recommendations of critical needs for advancing Parkinson Disease (PD) research in 2014 is to develop effective treatments for dopa-resistant features of PD. These features include symptoms such as gait and balance problems, and freezing of gait leading to falls. In order for these goals to be realized, dysfunctional motor patterns in patients with gait and balance problems need to be accurately defined and assessed using body-fixed sensors and other newer computation technology to enhance sensitivity and specificity of measurement to facilitate long-term follow-up. The proposed research will meet the challenge of determining appropriate intervention (L-DOPS) for dopa-resistant features of PD in improving gait and posture using innovative quantitative analyses derived from body-worn sensors. Injuries associated with fall incidences continue to pose a significant burden to persons with Parkinson's disease (PD) both in terms of human suffering and economic losses. Annual fall incidence rates range from 50-70% of patients with PD. Recurrent falls especially, are a major cause of disability in PD. The resulting loss of independence and treatment costs add substantially to the healthcare expenditures in PD which was estimated to be $27 billion annually2. This number may rise substantially in the coming decades as the entire US population ages. Any intervention that is cost effective at reducing fall risk could have important benefits for patients and families, and for the entire healthcare system. In this study, we will determine whether treatment with L- Dihydroxyphenylserine (L-DOPS, Northera) in addition to dopaminergic drugs will improve postural stability and activity of daily living, and reduce fall risk and/or severity of falls in PD patients.Falls, early in PD (within 5 years of diagnosis) probably arise from slowed locomotion. Slowed locomotion is corrected by dopaminergic drugs, hence falls early in PD are decreased by such drugs. Later in PD (5 or years after diagnosis) falls, recurrent falls, occur despite such drugs. There is evidence that falls late in PD occur because of impaired postural stability which does not respond to dopaminergic drugs or may be made worse by such drugs. A single fall, although serious, may be only partly related or even unrelated to PD. "Serious fall" is defined as: all four limbs hit the ground, the skull hits the ground, or there is soft tissue or bone injury. However, some people with PD fall repeatedly. In such patients the role of impaired postural stability was stressed. Although the mechanisms underlying impaired postural stability are not well-known in patients with PD, attention is focused on the noradrenergic system. L-DOPS, a drug that enhances norepinephrine levels in the peripheral and central nervous systems, has been shown to moderate orthostatic hypotension, and often improve some PD symptoms. There is evidence that mechanisms related to norepinephrine centers in the basal forebrain and the locus ceruleus play a role in maintaining postural stability in activities of daily living. They may play a role in preventing or ameliorating falls and freezing of gait. FOG is a major problem in patients with PD who fall. There is evidence that L-DOPS, by improving FOG, decreases risk of falls. Additionally, evidence indicates that L-DOPS decreases falls independent of improving FOG. Apathy, a major and disabling non-motor symptom of PD, may be related to decreased central norepinephrine levels. Apathy may be associated with slowed movements and slowed movements may contribute to falls. There is evidence that L-DOPS, by increasing central norepinephrine, may improve apathy and this may result in a decreased risk of falls.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson Disease
Keywords
L-dihydoxyphenylserine, L-DOPS, Northera

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
L-DOPS
Arm Type
Active Comparator
Arm Description
All participants will be on levodopa/carbidopa, and may be on additional dopaminergic drugs including dopamine agonists and/or monoamine type B oxidase inhibitors or amantadine. L-dihydoxyphenylserine will be added, administered as an oral capsule 3 times a day for 4 months. Dosing will begin at 100 mg of L-DOPS three times per day and titrated upward, by 100 mg three times a day, as tolerated. Tolerability will be evaluated based upon questionnaires, patient interviews, vital signs and investigator examination. In order to participate in the study, all subjects must be able to tolerate a minimum tolerated dose of 400 mg three times per day (1200mg/day). Subject maximum dose will be 600 mg three times per day (1800mg/day). Patients will be maintained on this dose for 4 months (until the cross-over). After a 7-day washout, participants will cross over to the Placebo arm.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
All participants will be on levodopa/carbidopa, and may be on additional dopaminergic drugs including dopamine agonists and/or monoamine type B oxidase inhibitors or amantadine. Placebo will be added, administered as an oral capsule 3 times a day for 4 months. Dosing will begin at 100 mg of placebo three times per day and titrated upward, by 100 mg three times a day, as tolerated. Tolerability will be evaluated based upon questionnaires, patient interviews, vital signs and investigator examination. In order to participate in the study, all subjects must be able to tolerate a minimum tolerated dose of 400 mg three times per day (1200mg/day). Subject maximum dose will be 600 mg three times per day (1800mg/day). Patients will be maintained on this dose for 4 months (until the cross-over) After a 7-day washout, participants will cross over to the L-DOPS arm.
Intervention Type
Drug
Intervention Name(s)
L-DOPS
Other Intervention Name(s)
L-dihydoxyphenylserine, Northera
Intervention Description
Added as described in the Arm/Group Descriptions.
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
sugar pill
Intervention Description
Added as described in the Arm/Group Descriptions.dded as described in the Arm/Group Descriptions.
Primary Outcome Measure Information:
Title
Motor Score
Description
Measured with United Parkinson's Disease Rating Scale (Part III 0-45) in the medication state of "on", "off", or both.
Time Frame
4 months
Title
Balance Score
Description
Measured using Barrow Neurologic Institute (BNI) Balance Scale 0-20, in the medication state of "on", "off", or both.
Time Frame
4 months
Title
Postural Stability
Description
Measured using a NeuroCom Equitest System, which tests sensory organization, motor control time, and postural sway measures, in the medication state of "on", "off", or both.
Time Frame
4 months
Title
Dynamic Stability
Description
Dynamic stability is measured by wearable devices (Inertial Measurement Units) that collect gait parameters during gait and postural transitions,in the medication state of "on", "off", or both.
Time Frame
4 months
Title
Falls
Description
Incidence of falls is self-report, in the medication state of "on", "off", or both.
Time Frame
4 months
Secondary Outcome Measure Information:
Title
Freezing of Gait (FOG)
Description
Measured using United Parkinson's Disease Rating Scale (FOG subtests 2.13 and 3.11) 0-8, in the medication state of "on", "off", or both.
Time Frame
4 months
Title
Apathy
Description
Measured using Apathy in Parkinson's Disease Questionnaire 0-42, in the medication state of "on", "off", or both.
Time Frame
4 months
Title
Orthostatic Hypotension
Description
Measured using Orthostatic Hypotension Symptom Assessment 0-10,in the medication state of "on", "off", or both.
Time Frame
4 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
83 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject has voluntarily signed and dated an informed consent form (ICF) prior to any participation in the study. Hoehn and Yahr Stage II, III, IV in an "on" state. Fell more than twice in past year. Montreal Cognitive Assessment (MOCA) score ≥ 24. Stable dose of levodopa, dopamine agonist, amantadine, and/or monoamine oxidase B inhibitor, i.e. unchanged for 3 months. Subject is ambulatory and able to walk ≥ 10 meters with/without the use of an assistive device. Exclusion Criteria: Patients with atypical Parkinson disorders that result in a high number of falls.These disorders include: Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), Primary Freezing of Gait (PFG), and Corticobasal Degeneration. Patients with dementia MOCA ≤ 23. Patients with symptomatic Orthostatic Hypotension being treated with midodrine, fludrocortisone or L-DOPS. Patients with uncontrolled hypertension. Patients with known allergies to L-DOPS or its excipients. Patients with major orthopedic problems of their hips or knees, and patients who need hip or knee replacements. Patient with schizophrenia, a schizo-affective disorder, or a bipolar disorder. Patients with hallucinations, psychoses, or delusions. Patients with a history of recent stroke or myocardial infarction.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Abraham Lieberman, MD
Organizational Affiliation
Barrow Neurological Institute/St. Joseph's Hospital and Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Barrow Neurological Institute/St. Joseph's Hospital and Medical Center
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85013
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson Disease

We'll reach out to this number within 24 hrs